Sam Brusco, Associate Editor02.15.22
Infectious disease remote monitoring and fluid analytics company CloudCath has earned U.S. Food and Drug Administration (FDA) clearance for its CloudCath System, a peritoneal dialysis (PD) data-driven, cloud-based, remote monitoring platform. According to the company, it is the first device of its kind and will be launched in select clinics over the coming months.
Continuous analytics can be conducted at home using the CloudCath System. It sends real-time notifications to the clinician and patient to facilitate dialysate fluid monitoring, which is required for safe PD home use.
"The opportunity to remotely and proactively manage our PD patients' addresses a major obstacle to greater PD adoption. Today's standard-of-care for patient monitoring is subjective. It relies on patients to self-monitor their dialysate fluid with either a decades-old "newspaper test," the ability to read text through fluid drainage lines, or waiting for signs of pain and discomfort in the abdomen," Glenn Chertow, M.D., MDH, Professor of Medicine in Nephrology at Stanford University School of Medicine told the press. "With the CloudCath solution, automated fluid analytics and real-time notifications will enable us to monitor and follow up with patients quickly, so they can stay home and on PD until a successful transplant."
At-home PD costs about 40 percent less than in-center dialysis for end-stage renal disease patients, about $53,000 annually per patient.
"FDA clearance of the CloudCath solution comes at a dynamic time in the dialysis market," said CloudCath co-founder and CEO Aly ElBadry. "With the 2019 Executive Order calling for increased use of at-home dialysis, CloudCath's automated sensing and advanced PD care algorithm build a stronger connection between clinicians and patients to help dialysis providers meet these goals. We are excited to deliver new health insights and care algorithms that aim to eventually reduce hospitalizations and improve quality of life for PD patients."
Continuous analytics can be conducted at home using the CloudCath System. It sends real-time notifications to the clinician and patient to facilitate dialysate fluid monitoring, which is required for safe PD home use.
"The opportunity to remotely and proactively manage our PD patients' addresses a major obstacle to greater PD adoption. Today's standard-of-care for patient monitoring is subjective. It relies on patients to self-monitor their dialysate fluid with either a decades-old "newspaper test," the ability to read text through fluid drainage lines, or waiting for signs of pain and discomfort in the abdomen," Glenn Chertow, M.D., MDH, Professor of Medicine in Nephrology at Stanford University School of Medicine told the press. "With the CloudCath solution, automated fluid analytics and real-time notifications will enable us to monitor and follow up with patients quickly, so they can stay home and on PD until a successful transplant."
At-home PD costs about 40 percent less than in-center dialysis for end-stage renal disease patients, about $53,000 annually per patient.
"FDA clearance of the CloudCath solution comes at a dynamic time in the dialysis market," said CloudCath co-founder and CEO Aly ElBadry. "With the 2019 Executive Order calling for increased use of at-home dialysis, CloudCath's automated sensing and advanced PD care algorithm build a stronger connection between clinicians and patients to help dialysis providers meet these goals. We are excited to deliver new health insights and care algorithms that aim to eventually reduce hospitalizations and improve quality of life for PD patients."